Detailed Information

Cited 17 time in webofscience Cited 18 time in scopus
Metadata Downloads

Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial

Full metadata record
DC Field Value Language
dc.contributor.authorHan, Kyung-Ah-
dc.contributor.authorChon, Suk-
dc.contributor.authorChung, Choon Hee-
dc.contributor.authorLim, Soo-
dc.contributor.authorLee, Kwan-Woo-
dc.contributor.authorBaik, SeiHyun-
dc.contributor.authorJung, Chang Hee-
dc.contributor.authorKim, Dong-Sun-
dc.contributor.authorPark, Kyong Soo-
dc.contributor.authorYoon, Kun-Ho-
dc.contributor.authorLee, In-Kyu-
dc.contributor.authorCha, Bong-Soo-
dc.contributor.authorSakatani, Taishi-
dc.contributor.authorPark, Sumi-
dc.contributor.authorLee, Moon-Kyu-
dc.date.accessioned2021-07-30T05:00:58Z-
dc.date.available2021-07-30T05:00:58Z-
dc.date.created2021-05-12-
dc.date.issued2018-10-
dc.identifier.issn1462-8902-
dc.identifier.urihttps://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/2675-
dc.description.abstractAim: To evaluate the efficacy and safety of ipragliflozin vs placebo as add-on therapy to metformin and sitagliptin in Korean patients with type 2 diabetes mellitus (T2DM). Methods: This double-blind, placebo-controlled, multi-centre, phase III study was conducted in Korea in 2015 to 2017. Patients were randomized to receive either ipragliflozin 50 mg/day or placebo once daily for 24 weeks in addition to metformin and sitagliptin. The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline to end of treatment (EOT). Results: In total, 143 patients were randomized and 139 were included in efficacy analyses (ipragliflozin: 73, placebo: 66). Baseline mean (SD) HbA1c levels were 7.90 (0.69)% for ipragliflozin add-on and 7.92 (0.79)% for placebo. The corresponding mean (SD) changes from baseline to EOT were -0.79 (0.59)% and 0.03 (0.84)%, respectively, in favour of ipragliflozin (adjusted mean difference -0.83% [95% CI -1.07 to -0.59]; P < .0001). More ipragliflozin-treated patients than placebo-treated patients achieved HbA1c target levels of <7.0% (44.4% vs 12.1%) and < 6.5% (12.5% vs 1.5%) at EOT (P < .05 for both). Fasting plasma glucose, fasting serum insulin, body weight and homeostatic model assessment of insulin resistance decreased significantly at EOT, in favour of ipragliflozin (adjusted mean difference -1.64 mmol/L, -1.50 mu U/mL, -1.72 kg, and -0.99, respectively; P < .05 for all). Adverse event rates were similar between groups (ipragliflozin: 51.4%; placebo: 50.0%). No previously unreported safety concerns were noted. Conclusions: Ipragliflozin as add-on to metformin and sitagliptin significantly improved glycaemic variables and demonstrated a good safety profile in Korean patients with inadequately controlled T2DM.-
dc.language영어-
dc.language.isoen-
dc.publisherWILEY-
dc.titleEfficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial-
dc.typeArticle-
dc.contributor.affiliatedAuthorKim, Dong-Sun-
dc.identifier.doi10.1111/dom.13394-
dc.identifier.scopusid2-s2.0-85050337091-
dc.identifier.wosid000444185800010-
dc.identifier.bibliographicCitationDIABETES OBESITY & METABOLISM, v.20, no.10, pp.2408 - 2415-
dc.relation.isPartOfDIABETES OBESITY & METABOLISM-
dc.citation.titleDIABETES OBESITY & METABOLISM-
dc.citation.volume20-
dc.citation.number10-
dc.citation.startPage2408-
dc.citation.endPage2415-
dc.type.rimsART-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaEndocrinology & Metabolism-
dc.relation.journalWebOfScienceCategoryEndocrinology & Metabolism-
dc.subject.keywordPlusDOUBLE-BLIND-
dc.subject.keywordPlusASIAN PATIENTS-
dc.subject.keywordPlusCOMBINATION THERAPY-
dc.subject.keywordPlusGLYCEMIC CONTROL-
dc.subject.keywordPlusPHASE-3 TRIAL-
dc.subject.keywordPlusDAPAGLIFLOZIN-
dc.subject.keywordPlusINHIBITOR-
dc.subject.keywordPlusMULTICENTER-
dc.subject.keywordPlus24-WEEK-
dc.subject.keywordAuthorDPP-4 inhibitor-
dc.subject.keywordAuthoripragliflozin-
dc.subject.keywordAuthorKorean-
dc.subject.keywordAuthorrandomized controlled trial-
dc.subject.keywordAuthorSGLT2 inhibitor-
dc.subject.keywordAuthortype 2 diabetes mellitus-
dc.identifier.urlhttps://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.13394-
Files in This Item
Appears in
Collections
서울 의과대학 > 서울 내과학교실 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Dong Sun photo

Kim, Dong Sun
COLLEGE OF MEDICINE (DEPARTMENT OF INTERNAL MEDICINE)
Read more

Altmetrics

Total Views & Downloads

BROWSE